We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two drug discovery approaches. The first approach is our TMAb™️ (Tumor Microenvironment Activated biologics) platform comprised of human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. Our lead program is targeting VISTA, a promising immune checkpoint inhibitor expressed on myeloid cells. Emerging nonclinical evidence has demonstrated that interaction of VISTA with its receptor (PSGL-1) is significantly enhanced by the acidic tumor microenvironment – a important differentiator of our research. We’re focused on unlocking the potential of VISTA with a human antibody and designed SNS-101 that selectively binds VISTA at low pH to activate T-cells and avoids on-target/off-tumor side effects, in preclinical studies.

The second approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Ascending
  • Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

    Experienced Biotechnology Executive to Lead Company’s Growth Strategy for Cancer Immunotherapies, Including Lead Clinical Candidate SNS-301 Sensei CEO John Celebi (Photo: Business Wire) GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical companyRead More

  • Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

    SNS-301 demonstrated a strong safety profile and promising immune responses in patients with biochemically recurrent prostate cancer SNS-301 is a first-in-class immunotherapy candidate emerging from Sensei’s SPIRIT platform that targets a novel embryonic antigen found on more than 20 types ofRead More

  • Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

    Sensei CMO Ildiko Csiki (Photo: Business Wire) August 21, 2018 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attackRead More

In the News

Sorting:
Sort Ascending
  • Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

    Experienced Biotechnology Executive to Lead Company’s Growth Strategy for Cancer Immunotherapies, Including Lead Clinical Candidate SNS-301 Sensei CEO John Celebi (Photo: Business Wire) GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical companyRead More

  • Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

    SNS-301 demonstrated a strong safety profile and promising immune responses in patients with biochemically recurrent prostate cancer SNS-301 is a first-in-class immunotherapy candidate emerging from Sensei’s SPIRIT platform that targets a novel embryonic antigen found on more than 20 types ofRead More

  • Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

    Sensei CMO Ildiko Csiki (Photo: Business Wire) August 21, 2018 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attackRead More

Signup For Update

sign up for newsletter and get the latest update